Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 745 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Syringe Injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of LY3074828 in Healthy Participants

NCT03188510
View directory record Official record
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 1, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
View directory record Official record
Conditions
Heart Failure
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

NCT02932943
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 1, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety Study of Cosmetic Tissue Augmentation in People of Color

NCT01147172
View directory record Official record
Conditions
Wrinkles
Interventions
Elevess
Device
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

NCT03135951
View directory record Official record
Conditions
Breast Cancer, Pharmacokinetics
Interventions
SPI-2012
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 1, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

NCT03783130
View directory record Official record
Conditions
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions
VRC-HIVRGP096-00-VP, Alum Adjuvant
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 1, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy

NCT05024344
View directory record Official record
Conditions
Nephrolithotomy, Percutaneous
Interventions
Erector Spinae Plane Block, Ropivacaine 0.5% Injectable Solution, Dexamethasone
Procedure · Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 1, 2026, 11:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

NCT05293626
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy (LHON)
Interventions
NR082 Injection, Injection needle
Drug · Device
Lead sponsor
Neurophth Therapeutics Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

NCT06280391
View directory record Official record
Conditions
Bronchiectasis
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

NCT03029208
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 1, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

NCT03627091
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 1, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

NCT00714597
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 1, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT07123090
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
Interventions
Sasanlimab, Palbociclib, Axitinib
Drug
Lead sponsor
Stephanie Berg
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 1, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

NCT01870986
View directory record Official record
Conditions
Healthy
Interventions
PF-06410293, Humira (adalimumab-EU), Humira (adalimumab-US)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 1, 2026, 11:12 PM EDT